All News

PCI Clinical Services (PCI) are pleased to announce a second phase 400 percent increase in Cyrogenic storage capabilities at our Rockford, Illinois site. The announcement follows our initial capital investment in specialist cryogenic storage in Rockfor...

Installation of state-of-the-art Harro Hӧfliger encapsulation unit expands clinical- and commercial-scale capacity for dry powder inhalation applications.

ImpactAir high performance air sampler range joins Cherwell’s portfolio of cleanroom microbiology products.

Inspection of up to 600 glass containers per minute using unique group testing.

Cold-EEZE is now Mylan's largest US consumer healthcare brand.

An important new treatment option for people with relapsing forms of multiple sclerosis demonstrating superior efficacy on the three major markers of disease activity compared with Rebif.

US commercial launch planned for late April.

Part of a longer term plan to increase capacity.

Offers more flexibility, better supply predictability and shorter lead times for more efficient and safer drug manufacture.

System can achieve separations with higher resolution, reproducibility and recovery then has previously been possible.

New production method for solid dispersions of docetaxel and paclitaxel.

Canada first country to launch Fiasp.

First targeted biologic therapy for adults with moderate-to-severe atopic dermatitis.

Unique mechanism: glutamate modulation and voltage-gated sodium channel blockade.

French Health Authority ANSM grants approval in the Mutual Recognition Procedure; the relevant health authorities are required to implement the new indication within 30 days.

Trumenba has been studied in a global clinical development program evaluating the vaccine in adolescents and adults.

Provides a cleaner, renewable energy source to reduce costs and lessen the CRO facility's impact on the environment.

Opdivo already approved by the EC for six indications in four distinct tumour types.

First NCE approved for PD patients with motor fluctuations in the US in more than a decade .

Significant investment in manufacturing diabetes medicines continues with new $85 million commitment in Indianapolis.

More than 80 contract manufactures were assessed by 26 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey.

Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions.

Developments correspond to generic products based on specialized pharmaceutical technologies.

Partnership to collaborate with industry to reduce risk and ensure optimal compliance for all members of the pharmaceutical supply chain.

New site will be used to complete premium injectable elastomeric component manufacturing.

The two new systems offer faster method development and the ability to quantify multiple proteins simultaneously.

PharmaCote ECxtra eliminates problems encountered during the hard chromium coating process.

5800-m2 facility will provide a range of GMP pharmaceutical testing services.

CDMO will manufacture and deliver Emla Patch - a local anaesthetic product.

TLE400 is a fixed-combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg.

Patients studied in the trial were reflective of those undergoing catheter ablation in routine clinical practice, providing highly relevant data to treating physicians.

Landmark real-world evidence from an international study of more than 300,000 patients with type-2 diabetes showed treatment with SGLT-2 inhibitors reduced risk of hospitalization for heart failure by 39% and all-cause mortality by 51%.

Agonists for GIT, CD27 and CD40 receptors in development for cancer immunotherapy exhibit significant in vitro- and in vivo activities.

New use of insulin was also reduced by 29% among patients taking Entresto compared to enalapril-treated patients.

Team led by Dr David Brough awarded £191,757 by public-private initiative driving early-stage drug discovery programmes.

Greater filtration capacity with a smaller footprint than conventional filters, improving economics for biopharmaceutical manufacturing.

Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible wit...

PIC/S membership accelerating international interest with market forecast to reach US$115bn by 2024.

Kisqali plus letrozole showed treatment benefit across all patient subgroups regardless of disease burden or tumour location.

The Xelum platform combines dosing, mixing, granulating and pressing, paving the way for more efficient tablet manufacturing.

Cinryze is the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics.

Nowadays, efficient process research and development are, more than ever, an absolute must for contract manufacturers and API manufacturers. New products/processes need to be pushed through to market readiness faster and faster. However, development de...

Welcome to visit us at booth 802 during CPhi Russia 2017 on Mar.28-30.

Only anti-PD-1 therapy approved for the treatment of patients with difficult-to-treat cHL regardless of prior stem cell transplantation or use of brentuximab vedotin

Supports small molecule ion channel drug discovery, from initial screening to development candidate.

For success in the biosimilars sector, manufacturers must adopt QbD, DoE and PAT initiatives.

Alliance brings together eye care and CRISPR innovators to develop transformative medicines for patients.

Zavicefta treat complicated infections caused By Gram-negative bacteria.

Dietary supplement products "misbranded" and unapproved new drugs being marketed with drug claims despite not being approved for any use.

Current product portfolio includes a range of specialty alkoxide bases and borane derivatives.

Together with Oxaliplatin and Folinic Acid, 5-FU is used in the most successful first line treatment of colon cancer (FOLFOX). As a second line treatment, it is successfully applied with Folinic Acid and Irinotecan (FOLFIRI). We can provide all these o...

With DCS Pharma your registration will be smooth because we have the most reliable source available, with complete documentation for regulated markets and full regulatory support.

Settlement provides Mylan with global licenses for its trastuzumab product.

Data suggest an alternative option for patients.

parodontax - first toothpaste proven to help consumers leave bleeding gums behind.

BI 836858 was previously granted orphan drug designation for the treatment of patients with AML.

Work on a second-generation fusion protein due to start in 2017 at Patheon's manufacturing facility in Brisbane.

The tablets are indicated for the treatment of major depressive disorder.

Collaboration is the second to evaluate a combination of CV301 with a checkpoint inhibitor.

Q Laboratories, Inc. (Cincinnati, Ohio) has added another tool to their microbial identification capabilities by acquiring the Bruker MALDI Biotyper®. This technology allows for rapid, cost-effective, accurate identification of thousands of microorgani...

Tooling products focused on increasing productivity for the tablet manufacturer.

Partnership formed to evaluate the impact of Amplycell’s novel cell fitness technology on expression capacity of Horizon’s bioproduction cell line.

Expansion plan comprises company's largest investment in the US.

The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.

He succeeds Dr Francis Cuss, 62, who will retire from the company.

Application seeks to expand Vraylar label to include Phase III clinical data for the maintenance treatment of schizophrenia.

Expanded week of dedicated sessions and trends on the world’s second largest pharma market.

Easy scale-up with Pharmatec pilot fermenter.

Cosentyx has shown superior and sustained results versus both Stelara and Enbrel, delivering long-lasting clear or almost clear skin.

Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF.

Provides hope for patients with severe asthma, who currently have very limited treatment options.

Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

Represents Biocad's third authorized medicine for the treatment of relapsing-remitting multiple sclerosis.

Alcami will use the D8 DISCOVER HTS to add XRD capabilities to their laboratory service portfolio.

Merck's €42 million investment expands the allergies business on a global scale.

MEDI8897 has been engineered to have a long half-life so that only one dose would be needed for the entire RSV season.

More patients now able to receive a standard-of-care treatment with Erbitux plus Folfiri or Folfox.

Reinforces position as a supplier of excipients and raw materials for the pharmaceutical and biopharmaceutical industries.

Funding will be used to prepare for international clinical study to evaluate the Company’s ELISA-based urine test for prostate cancer.

Affinivax’s MAPS vaccine technology overcomes the limitations of current conjugate vaccine technology, creating a MAPS pneumococcal vaccine that enables broader protection.

Government plans to construct 10 factories for the manufacturing of biosimilars by 2020, with an additional investment of $265.3 million.

CPHI Middle East & Africa is a natural progression and rebrand of the rapid growth seen at CPHI Istanbul.

Acquisition enhances Lilly's existing pain management.

Second Biologics License Application accepted by the FDA for avelumab.

Innovation is being driven increasingly by smaller, possibly more agile, companies.

Supports a wide range of needs across the biopharma development cycle.

New model incorporates an improved algorithm to simplify test creation and accelerate test completion.

Partnership leverages Lonza's expertise in large-scale mammalian cell culture facilities alongside Sanofi's strength in developing and launching biologics based treatments.

If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment.

If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation.

Recall due to potential lack of sterility assurance.

Compared with warfarin, Pradaxa was associated with a 26% reduced risk of stroke and a 20% reduced risk of major bleeding.

Tool explores the time course of drug exposure, biomarker response and outcome.

Antibody levels maintained against multiple targets 6 months post vaccination.

Portfolio includes treatments for Crohn's disease, ulcerative colitis, and bowel preparation before endoscopy.

Approval of the automated mini-doser marks first hands-free administration option for a PCSK9 inhibitor in Europe.

Experimental vaccine targets mosquito saliva.

Aids R&D initiatives to advance precision medicine.

Modified baker’s yeasts cause an immune response and the production of lymphocyte killers, which detect and eliminate cancerous cells.

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016.

New kit enables covalent conjugation of antibodies and proteins to magnetic particles.

The acquired business is now known as Recipharm Pharmaservices Private Ltd.

Distributors, API manufacturers, and machinery providers seeing high demand across Russia and CIS.

Trial data further supports the existing clinical profile of CT-P13 in inflammatory bowel disease.

Unique sensor technology tracks inhalation profiles and technique.

Sartorius is offering its expertise to enhance scientific education and practice.

Study showed that people whose disease expressed PD-L1 and were treated with Tecentriq plus Avastin had a 36% reduction in the risk of their disease worsening

Company achieves the £9 million calendar year royalty cap on net sales of Ellipta products a year earlier than previously guided.

Steroid-free Spiriva Respimat now approved as asthma treatment for age 6 and older.

Expands softgel development and manufacturing capabilities and capacity.

The proposed biosimilar to Neulasta is used to reduce the duration of neutropenia and the incidence of fever associated with neutropenia in adult patients treated with chemotherapy in certain types of cancer.

More than 50% of patients in three clinical studies who used Siliq achieved total skin clearance within a year.

Investment in a inductively coupled plasma mass spectrometry system is a move to address the updated ICH Q3D regulatory guidelines on elemental impurities.

Trends include ‘human factor’ principles, with ‘individualised packaging and serialisation’ as the integral solutions of the future.

Generic Pharmaceutical Association becomes Association for Accessible Medicines.

Complidermol 5α PLUS tackles not only the known hormonal factor, but also the oxidative and inflammatory factors, new pathophysiological factors identified as causes of this condition.

Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU.

The presentations highlight Alzheon’s ‘precision medicine’ approach to drug development for Alzheimer’s disease.